[Tactivin in combined treatment of patients with pulmonary tuberculosis associated with gastrointestinal diseases].

Abstract

Tactivin was tried in combined therapy of 49 new-onset cases with destructive pulmonary tuberculosis and gastrointestinal lesions. 52 controls received antibacterial drugs alone. Tactivin increased T-lymphocyte count and improved their subpopulations proportion in a shorter period of time. Immunochemotherapy contributed to efficacy of the main and associated disease treatment. Healing of the destruction foci occurred in 87% versus 70% in controls, side effects of antibacterial drugs and exacerbations of gastrointestinal diseases arose 2-2.5 times less frequently.

• Authors: E M Zhukova
• Journal: Problemy tuberkuleza (Probl Tuberk) Issue 3 Pg. 25-7 ( 1995) ISSN: 0032-9533 [Print] Russia (Federation)
• Vernacular Title: Taktivin v kompleksnoĭ terapii bol'nykh tuberkulezom legkikh, sochetaiushchimsia s zabolevaniiami zheludochno-kishechnogo trakta.
• PMID: 7617628 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Antitubercular Agents
• Peptides
• Thymus Extracts
• T-activin

Topics

• Adjuvants, Immunologic (therapeutic use)
• Adolescent
• Adult
• Antitubercular Agents (therapeutic use)
• Cholecystitis (complications)
• Combined Modality Therapy
• Gastritis (complications)
• Gastrointestinal Diseases (complications)
• Humans
• Middle Aged
• Peptic Ulcer (complications)
• Peptides (therapeutic use)
• Rosette Formation
• Thymus Extracts (therapeutic use)
• Tuberculosis, Pulmonary (complications, drug therapy, immunology)